0001209191-22-023860.txt : 20220408 0001209191-22-023860.hdr.sgml : 20220408 20220408162101 ACCESSION NUMBER: 0001209191-22-023860 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220406 FILED AS OF DATE: 20220408 DATE AS OF CHANGE: 20220408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rovaldi Christopher CENTRAL INDEX KEY: 0001706040 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 22817261 MAIL ADDRESS: STREET 1: C/O ACCELERON PHARMA INC. STREET 2: 128 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-513-8774 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-06 0 0001664710 Keros Therapeutics, Inc. KROS 0001706040 Rovaldi Christopher C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421 0 1 0 0 Chief Operating Officer Common Stock 2022-04-06 4 M 0 1728 16.00 A 1728 D Common Stock 2022-04-06 4 S 0 1728 65.00 D 0 D Employee Stock Option (right to buy) 16.00 2022-04-06 4 M 0 1728 0.00 D 2030-04-07 Common Stock 1728 8002 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. /s/ Esther Cho, Attorney-in-Fact 2022-04-08